{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:49:24Z","timestamp":1791326964020,"version":"4.3.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,15]]},"DOI":"10.1093\/hmg\/ddl094","type":"journal-article","created":{"date-parts":[[2006,4,13]],"date-time":"2006-04-13T20:27:06Z","timestamp":1144960026000},"page":"1713-1721","source":"Crossref","is-referenced-by-count":125,"title":["Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6\/2 transgenic mouse model of Huntington's disease"],"prefix":"10.1093","volume":"15","author":[{"given":"Maria","family":"Bj\u00f6rkqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Peters\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Bacos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Norl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalija","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Sundler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian P.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Brundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hindrik","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,4,13]]},"reference":[{"key":"key\n\t\t\t\t20171011153835_DDL094C1","doi-asserted-by":"crossref","unstructured":"Sanberg, P.R., Fibiger, H.C. and Mark, R.F. ( 1981 ) Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. , 1 , 407 \u2013409.","DOI":"10.5694\/j.1326-5377.1981.tb135681.x"},{"key":"key\n\t\t\t\t20171011153835_DDL094C2","doi-asserted-by":"crossref","unstructured":"Djousse, L., Knowlton, B., Cupples, L.A., Marder, K., Shoulson, I. and Myers, R.H. ( 2002 ) Weight loss in early stage of Huntington's disease. Neurology , 59 , 1325 \u20131330.","DOI":"10.1212\/01.WNL.0000031791.10922.CF"},{"key":"key\n\t\t\t\t20171011153835_DDL094C3","doi-asserted-by":"crossref","unstructured":"Kirkwood, S.C., Su, J.L., Conneally, P. and Foroud, T. ( 2001 ) Progression of symptoms in the early and middle stages of Huntington disease. Arch. Neurol. , 58 , 273 \u2013278.","DOI":"10.1001\/archneur.58.2.273"},{"key":"key\n\t\t\t\t20171011153835_DDL094C4","doi-asserted-by":"crossref","unstructured":"Heuser, I.J., Chase, T.N. and Mouradian, M.M. ( 1991 ) The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease. Biol Psychiatry , 30 , 943 \u2013952.","DOI":"10.1016\/0006-3223(91)90007-9"},{"key":"key\n\t\t\t\t20171011153835_DDL094C5","doi-asserted-by":"crossref","unstructured":"Leblhuber, F., Peichl, M., Neubauer, C., Reisecker, F., Steinparz, F.X., Windhager, E. and Maschek, W. ( 1995 ) Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea. J. Neurol. Sci. , 132 , 76 \u201379.","DOI":"10.1016\/0022-510X(95)00114-H"},{"key":"key\n\t\t\t\t20171011153835_DDL094C6","doi-asserted-by":"crossref","unstructured":"Farrer, L.A. ( 1985 ) Diabetes mellitus in Huntington disease. Clin. Genet. , 27 , 62 \u201367.","DOI":"10.1111\/j.1399-0004.1985.tb00185.x"},{"key":"key\n\t\t\t\t20171011153835_DDL094C7","doi-asserted-by":"crossref","unstructured":"Kremer, H.P., Roos, R.A., Dingjan, G., Marani, E. and Bots, G.T. ( 1990 ) Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. , 49 , 371 \u2013382.","DOI":"10.1097\/00005072-199007000-00002"},{"key":"key\n\t\t\t\t20171011153835_DDL094C8","doi-asserted-by":"crossref","unstructured":"Kremer, H.P., Roos, R.A., Dingjan, G.M., Bots, G.T., Bruyn, G.W. and Hofman, M.A. ( 1991 ) The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci. Lett. , 132 , 101 \u2013104.","DOI":"10.1016\/0304-3940(91)90443-W"},{"key":"key\n\t\t\t\t20171011153835_DDL094C9","doi-asserted-by":"crossref","unstructured":"Petersen, A., Gil, J., Maat-Schieman, M.L., Bjorkqvist, M., Tanila, H., Araujo, I.M., Smith, R., Popovic, N., Wierup, N., Norlen, P. et\u00a0al . ( 2005 ) Orexin loss in Huntington's disease. Hum. Mol. Genet. , 14 , 39 \u201347.","DOI":"10.1093\/hmg\/ddi004"},{"key":"key\n\t\t\t\t20171011153835_DDL094C10","doi-asserted-by":"crossref","unstructured":"Menalled, L.B. and Chesselet, M.F. ( 2002 ) Mouse models of Huntington's disease. Trends Pharmacol. Sci. , 23 , 32 \u201339.","DOI":"10.1016\/S0165-6147(00)01884-8"},{"key":"key\n\t\t\t\t20171011153835_DDL094C11","doi-asserted-by":"crossref","unstructured":"Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et\u00a0al . ( 1996 ) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell , 87 , 493 \u2013506.","DOI":"10.1016\/S0092-8674(00)81369-0"},{"key":"key\n\t\t\t\t20171011153835_DDL094C12","doi-asserted-by":"crossref","unstructured":"Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. ( 1997 ) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell , 90 , 537 \u2013548.","DOI":"10.1016\/S0092-8674(00)80513-9"},{"key":"key\n\t\t\t\t20171011153835_DDL094C13","doi-asserted-by":"crossref","unstructured":"Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A., Bates, G.P., Dunnett, S.B. and Morton, A.J. ( 1999 ) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. , 19 , 3248 \u20133257.","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999"},{"key":"key\n\t\t\t\t20171011153835_DDL094C14","doi-asserted-by":"crossref","unstructured":"Lione, L.A., Carter, R.J., Hunt, M.J., Bates, G.P., Morton, A.J. and Dunnett, S.B. ( 1999 ) Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J. Neurosci. , 19 , 10428 \u201310437.","DOI":"10.1523\/JNEUROSCI.19-23-10428.1999"},{"key":"key\n\t\t\t\t20171011153835_DDL094C15","doi-asserted-by":"crossref","unstructured":"Stack, E.C., Kubilus, J.K., Smith, K., Cormier, K., Del Signore, S.J., Guelin, E., Ryu, H., Hersch, S.M. and Ferrante, R.J. ( 2005 ) Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice. J. Comp. Neurol. , 490 , 354 \u2013370.","DOI":"10.1002\/cne.20680"},{"key":"key\n\t\t\t\t20171011153835_DDL094C16","doi-asserted-by":"crossref","unstructured":"Hurlbert, M.S., Zhou, W., Wasmeier, C., Kaddis, F.G., Hutton, J.C. and Freed, C.R. ( 1999 ) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes , 48 , 649 \u2013651.","DOI":"10.2337\/diabetes.48.3.649"},{"key":"key\n\t\t\t\t20171011153835_DDL094C17","doi-asserted-by":"crossref","unstructured":"Luesse, H.G., Schiefer, J., Spruenken, A., Puls, C., Block, F. and Kosinski, C.M. ( 2001 ) Evaluation of R6\/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav. Brain Res. , 126 , 185 \u2013195.","DOI":"10.1016\/S0166-4328(01)00261-3"},{"key":"key\n\t\t\t\t20171011153835_DDL094C18","doi-asserted-by":"crossref","unstructured":"Bjorkqvist, M., Fex, M., Renstrom, E., Wierup, N., Petersen, A., Gil, J., Bacos, K., Popovic, N., Li, J.Y., Sundler, F. et\u00a0al . ( 2005 ) The R6\/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis. Hum. Mol. Genet. , 14 , 565 \u2013574.","DOI":"10.1093\/hmg\/ddi053"},{"key":"key\n\t\t\t\t20171011153835_DDL094C19","doi-asserted-by":"crossref","unstructured":"Fain, J.N., Del Mar, N.A., Meade, C.A., Reiner, A. and Goldowitz, D. ( 2001 ) Abnormalities in the functioning of adipocytes from R6\/2 mice that are transgenic for the Huntington's disease mutation. Hum. Mol. Genet. , 10 , 145 \u2013152.","DOI":"10.1093\/hmg\/10.2.145"},{"key":"key\n\t\t\t\t20171011153835_DDL094C20","doi-asserted-by":"crossref","unstructured":"Ribchester, R.R., Thomson, D., Wood, N.I., Hinks, T., Gillingwater, T.H., Wishart, T.M., Court, F.A. and Morton, A.J. ( 2004 ) Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. Eur. J. Neurosci. , 20 , 3092 \u20133114.","DOI":"10.1111\/j.1460-9568.2004.03783.x"},{"key":"key\n\t\t\t\t20171011153835_DDL094C21","doi-asserted-by":"crossref","unstructured":"Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E.E., Doherty, P., Davies, S.W. and Bates, G.P. ( 1999 ) Formation of polyglutamine inclusions in non-CNS tissue. Hum. Mol. Genet. , 8 , 813 \u2013822.","DOI":"10.1093\/hmg\/8.5.813"},{"key":"key\n\t\t\t\t20171011153835_DDL094C22","doi-asserted-by":"crossref","unstructured":"Baxter, J.D. and Rousseau, G.G. ( 1979 ) Glucocorticoid hormone action: an overview. Monogr Endocrinol. , 12 , 1 \u201324.","DOI":"10.1007\/978-3-642-81265-1_1"},{"key":"key\n\t\t\t\t20171011153835_DDL094C23","unstructured":"Owens, M.J. and Nemeroff, C.B. ( 1991 ) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. , 43 , 425 \u2013473."},{"key":"key\n\t\t\t\t20171011153835_DDL094C24","doi-asserted-by":"crossref","unstructured":"Gonzalez De Aguilar, J.L., Rene, F., Dupuis, L. and Loeffler, J.P. ( 2003 ) Neuroendocrinology of neurodegenerative diseases. Insights from transgenic mouse models. Neuroendocrinology , 78 , 244 \u2013252.","DOI":"10.1159\/000074445"},{"key":"key\n\t\t\t\t20171011153835_DDL094C25","doi-asserted-by":"crossref","unstructured":"Ristow, M. ( 2004 ) Neurodegenerative disorders associated with diabetes mellitus. J. Mol. Med. , 82 , 510 \u2013529.","DOI":"10.1007\/s00109-004-0552-1"},{"key":"key\n\t\t\t\t20171011153835_DDL094C26","doi-asserted-by":"crossref","unstructured":"Beal, M.F. and Ferrante, R.J. ( 2004 ) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. , 5 , 373 \u2013384.","DOI":"10.1038\/nrn1386"},{"key":"key\n\t\t\t\t20171011153835_DDL094C27","doi-asserted-by":"crossref","unstructured":"Weeks, R.A., Piccini, P., Harding, A.E. and Brooks, D.J. ( 1996 ) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. , 40 , 49 \u201354.","DOI":"10.1002\/ana.410400110"},{"key":"key\n\t\t\t\t20171011153835_DDL094C28","doi-asserted-by":"crossref","unstructured":"Augood, S.J., Faull, R.L. and Emson, P.C. ( 1997 ) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. , 42 , 215 \u2013221.","DOI":"10.1002\/ana.410420213"},{"key":"key\n\t\t\t\t20171011153835_DDL094C29","doi-asserted-by":"crossref","unstructured":"Cha, J.H., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penney, J.B., Bates, G.P. and Young, A.B. ( 1998 ) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc. Natl. Acad. Sci. USA , 95 , 6480 \u20136485.","DOI":"10.1073\/pnas.95.11.6480"},{"key":"key\n\t\t\t\t20171011153835_DDL094C30","doi-asserted-by":"crossref","unstructured":"Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch, S.M., Mouradian, M.M., Young, A.B., Tanese, N. and Krainc, D. ( 2002 ) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science , 2 , 2 .","DOI":"10.1126\/science.1072613"},{"key":"key\n\t\t\t\t20171011153835_DDL094C31","doi-asserted-by":"crossref","unstructured":"Saiardi, A. and Borrelli, E. ( 1998 ) Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. Mol. Endocrinol. , 12 , 1133 \u20131139.","DOI":"10.1210\/me.12.8.1133"},{"key":"key\n\t\t\t\t20171011153835_DDL094C32","doi-asserted-by":"crossref","unstructured":"Cote, T.E., Felder, R., Kebabian, J.W., Sekura, R.D., Reisine, T. and Affolter, H.U. ( 1986 ) D-2 dopamine receptor-mediated inhibition of pro-opiomelanocortin synthesis in rat intermediate lobe. Abolition by pertussis toxin or activators of adenylate cyclase. J. Biol. Chem. , 261 , 4555 \u20134561.","DOI":"10.1016\/S0021-9258(17)38537-X"},{"key":"key\n\t\t\t\t20171011153835_DDL094C33","doi-asserted-by":"crossref","unstructured":"Pardy, K., Carter, D. and Murphy, D. ( 1990 ) Dopaminergic mediation of physiological changes in proopiomelanocortin messenger ribonucleic acid expression in the neurointermediate lobe of the rat pituitary. Endocrinology , 126 , 2960 \u20132964.","DOI":"10.1210\/endo-126-6-2960"},{"key":"key\n\t\t\t\t20171011153835_DDL094C34","doi-asserted-by":"crossref","unstructured":"Jagoe, R.T. and Goldberg, A.L. ( 2001 ) What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Metab. Care , 4 , 183 \u2013190.","DOI":"10.1097\/00075197-200105000-00003"},{"key":"key\n\t\t\t\t20171011153835_DDL094C35","doi-asserted-by":"crossref","unstructured":"Khaleeli, A.A., Edwards, R.H., Gohil, K., McPhail, G., Rennie, M.J., Round, J. and Ross, E.J. ( 1983 ) Corticosteroid myopathy: a clinical and pathological study. Clin. Endocrinol (Oxf) , 18 , 155 \u2013166.","DOI":"10.1111\/j.1365-2265.1983.tb03198.x"},{"key":"key\n\t\t\t\t20171011153835_DDL094C36","doi-asserted-by":"crossref","unstructured":"Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A. et\u00a0al . ( 2003 ) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA , 100 , 2041 \u20132046.","DOI":"10.1073\/pnas.0437870100"},{"key":"key\n\t\t\t\t20171011153835_DDL094C37","doi-asserted-by":"crossref","unstructured":"Messing, R.O. and Simon, R.P. ( 1986 ) Seizures as a manifestation of systemic disease. Neurol. Clin. , 4 , 563 \u2013584.","DOI":"10.1016\/S0733-8619(18)30963-0"},{"key":"key\n\t\t\t\t20171011153835_DDL094C38","doi-asserted-by":"crossref","unstructured":"Cameron, H.A. and Gould, E. ( 1994 ) Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience , 61 , 203 \u2013209.","DOI":"10.1016\/0306-4522(94)90224-0"},{"key":"key\n\t\t\t\t20171011153835_DDL094C39","doi-asserted-by":"crossref","unstructured":"Gil, J., Leist, M., Popovic, N., Brundin, P. and Petersen, A. ( 2004 ) Asialoerythropoetin is not effective in the R6\/2 line of Huntington's disease mice. BMC Neurosci. , 5 , 17 .","DOI":"10.1186\/1471-2202-5-17"},{"key":"key\n\t\t\t\t20171011153835_DDL094C40","doi-asserted-by":"crossref","unstructured":"Gil, J.M., Mohapel, P., Araujo, I.M., Popovic, N., Li, J.Y., Brundin, P. and Petersen, A. ( 2005 ) Reduced hippocampal neurogenesis in R6\/2 transgenic Huntington's disease mice. Neurobiol. Dis. , 20 , 744 \u2013751.","DOI":"10.1016\/j.nbd.2005.05.006"},{"key":"key\n\t\t\t\t20171011153835_DDL094C41","doi-asserted-by":"crossref","unstructured":"Wong, E.Y. and Herbert, J. ( 2006 ) Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus. Neuroscience , 137 , 83 \u201392.","DOI":"10.1016\/j.neuroscience.2005.08.073"},{"key":"key\n\t\t\t\t20171011153835_DDL094C42","doi-asserted-by":"crossref","unstructured":"Sapolsky, R.M. ( 2000 ) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry. , 57 , 925 \u2013935.","DOI":"10.1001\/archpsyc.57.10.925"},{"key":"key\n\t\t\t\t20171011153835_DDL094C43","doi-asserted-by":"crossref","unstructured":"Arlt, W. and Stewart, P.M. ( 2005 ) Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab. Clin. North. Am. , 34 , 293 \u2013313. viii .","DOI":"10.1016\/j.ecl.2005.01.002"},{"key":"key\n\t\t\t\t20171011153835_DDL094C44","doi-asserted-by":"crossref","unstructured":"Bailer, U.F. and Kaye, W.H. ( 2003 ) A review of neuropeptide and neuroendocrine dysregulation in anorexia and bulimia nervosa. Curr. Drug Targets CNS Neurol. Disord. , 2 , 53 \u201359.","DOI":"10.2174\/1568007033338689"},{"key":"key\n\t\t\t\t20171011153835_DDL094C45","unstructured":"Adinoff, B., Iranmanesh, A., Veldhuis, J. and Fisher, L. ( 1998 ) Disturbances of the stress response: the role of the HPA axis during alcohol withdrawal and abstinence. Alcohol Health Res. World , 22 , 67 \u201372."},{"key":"key\n\t\t\t\t20171011153835_DDL094C46","doi-asserted-by":"crossref","unstructured":"Armanini, D., Vecchio, F., Basso, A., Milone, F.F., Simoncini, M., Fiore, C., Mattarello, M.J., Sartorato, P. and Karbowiak, I. ( 2003 ) Alzheimer's disease: pathophysiological implications of measurement of plasma cortisol, plasma dehydroepiandrosterone sulfate, and lymphocytic corticosteroid receptors. Endocrine , 22 , 113 \u2013118.","DOI":"10.1385\/ENDO:22:2:113"},{"key":"key\n\t\t\t\t20171011153835_DDL094C47","doi-asserted-by":"crossref","unstructured":"Shoulson, I. and Fahn, S. ( 1979 ) Huntington disease: clinical care and evaluation. Neurology , 29 , 1 \u20133.","DOI":"10.1212\/WNL.29.1.1"},{"key":"key\n\t\t\t\t20171011153835_DDL094C48","doi-asserted-by":"crossref","unstructured":"Brommage, R. ( 2003 ) Validation and calibration of DEXA body composition in mice. Am. J. Physiol. Endocrinol. Metab. , 285 , E454 \u2013E459.","DOI":"10.1152\/ajpendo.00470.2002"}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/article-pdf\/15\/10\/1713\/6949911\/ddl094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T12:58:11Z","timestamp":1627217891000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/hmg\/article\/15\/10\/1713\/2355909\/Progressive-alterations-in-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,13]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2006,4,13]]},"published-print":{"date-parts":[[2006,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddl094","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13937.471441","asserted-by":"object"}]},"ISSN":["1460-2083","0964-6906"],"issn-type":[{"value":"1460-2083","type":"electronic"},{"value":"0964-6906","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,5,15]]},"published":{"date-parts":[[2006,4,13]]}}}